Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of intrathecal LY4256984 in sporadic amyotrophic lateral sclerosis
NL-OMON61624Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY4256984 in amyotrophic lateral sclerosis (ALS), sponsored by Eli Lilly and Company. Primary endpoint: Safety. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
LY4256984
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON61624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61624.